Antibody response after varicella vaccination similar in children treated with budesonide inhalation suspension (BIS) or nonsteroidal conventional asthma therapy (NSCAT)
K. Murphy, K. Ververeli, B. M. Harvey, A. L. Duke, J. Chapas-Crilly, T. Uryniak, E. Lyzell, W. Mezzanotte (Omaha, Collegeville, Jonesboro, Little Rock, Wilmington, United States Of America)
Source: Annual Congress 2006 - Therapy in childhood asthma I
Session: Therapy in childhood asthma I
Session type: Thematic Poster Session
Number: 4087
Disease area: Airway diseases, Paediatric lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Murphy, K. Ververeli, B. M. Harvey, A. L. Duke, J. Chapas-Crilly, T. Uryniak, E. Lyzell, W. Mezzanotte (Omaha, Collegeville, Jonesboro, Little Rock, Wilmington, United States Of America). Antibody response after varicella vaccination similar in children treated with budesonide inhalation suspension (BIS) or nonsteroidal conventional asthma therapy (NSCAT). Eur Respir J 2006; 28: Suppl. 50, 4087
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Suboptimal persistence with inhaled corticosteroid (ICS) mono-therapy among children with persistent asthma in the UK Source: Eur Respir J 2006; 28: Suppl. 50, 709s Year: 2006
Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Is the combination of long-acting β2 -agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma? Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015
Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2 agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003
Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2 -agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011
Efficacy and safety of inhaled corticosteroid‘s (ICS) and long-acting beta-agonist‘s (LABA) combination in asthma (A) patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Differences between asthmatics and nonasthmatics hospitalised with influenza A infection Source: Eur Respir J 2013; 41: 824-831 Year: 2013
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017
Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), demonstrates dose-response efficacy in patients symptomatic on non-steroidal asthma therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Treatment with inhaled corticosteroids (ICS), smoking and asthma control in real clinical practice Source: Annual Congress 2010 - Pharmacological treatment in primary care Year: 2010
Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β2 agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003
Effect of inhaled SNG001 (interferon-beta 1a) on sputum and blood antiviral biomarkers following a respiratory virus infection in asthmatic subjects Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Use of step-down design to study dose comparability of budesonide (B) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003
Efficacy of high dose inhaled DSCG on asthma control in young children Source: Annual Congress 2008 - Wheezing in preschool children Year: 2008
Meta-analysis of inhaled corticosteroids response in children with asthma. Source: International Congress 2019 – Paediatric asthma: risk factors, biomarkers and the basics Year: 2019